Mixture designs in the optimisation of PLGA nanoparticles: Influence of organic phase composition on β-aescin encapsulation

Journal of Microencapsulation

Volumn 29, Issue 2, 2012, Pages 115-125

  Van De Ven, H ^a   Vandervoort, J ^a   Weyenberg, W ^a   Apers, S ^a   Ludwig, A ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

antileishmanial; experimental design; particle size; salting out; saponins; solvent evaporation

Indexed keywords

BETA ESCIN; DIMETHYL SULFOXIDE; NANOPARTICLE; POLYGLACTIN; POLYMER; SOLVENT;

ANALYTIC METHOD; ARTICLE; CHEMICAL COMPOSITION; CONCENTRATION (PARAMETERS); DISPERSION; EMULSIFICATION SOLVENT EVAPORATION; EMULSION; EVAPORATION; NANOENCAPSULATION; ORGANIC PHASE COMPOSITION; PARTICLE SIZE; SALTING OUT TECHNIQUE; VISCOSITY; ZETA POTENTIAL;

EMULSIONS; ESCIN; LACTIC ACID; LEISHMANIA; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; VISCOSITY;

EID: 84856940727     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.630108     Document Type: Article

References (46)

1. Aggarwal P, Hall JB, McLeland CB, Dobrovolskaia MA, McNeil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Delivery Rev, 2009;61:428-37.
2. Allémann E, Gurny R, Doelker E. Preparation of aqueous polymeric nanodispersions by a reversible salting-out process, influence of process parameters on particles size. Int J Pharm, 1992;87:247-53.
3. Apers S, Naessens T, Pieters L, Vlietinck A. Densitometric thin-layer chromatographic determination of aescin in a herbal medicinal product containing Aesculus and Vitis dry extracts. J Chromatogr A, 2006;1112: 165-70.
4. Bilati U, Allémann E, Doelker E. Development of a nanoprecipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci, 2005;24:67-75. (Pubitemid 40051288)
5. Blanco MD, Alonso MJ. Development and characterization of proteinloaded poly(lactide-co-glycolide) nanospheres. Eur J Pharm Biopharm, 1997;43:287-94.
6. Breunig M, Bauer S, Goepferich A. Polymers and nanoparticles: Intelligent tools for intracellular targeting. Eur J Pharm Biopharm, 2008;68:112-28. (Pubitemid 350181412)
7. Briones E, Colino CI, Lanao JM. Delivery systems to increase the selectivity of antibiotics in phagocytic cells. J Controlled Release, 2008;125:210-27.
8. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M. Visceral leishmaniasis: What are the needs for diagnosis, treatment and control. Nat Rev Microbiol, 2007;5:S7-S16. (Pubitemid 350011772)
9. Chellat F, Merhi Y, Moreau A, Yahia L. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials, 2005;26: 7260-75. (Pubitemid 41133578)
10. Clift MJD, Rothen-Rutishauser B, Brown DM, Duffin R, Donaldson K, Proudfoot L, Guy K, Stone V. The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. Toxicol Appl Pharmacol, 2008;232:418-27.
11. Cohen-Sela E, Teitlboim S, Chorny M, Koroukhov N, Danenberg HD, Gao J, Golomb G. Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: Formulations of mithramycin and bioactivity. J Pharm Sci, 2009;98(4):1452-62.
12. Date AA, Joshi MD, Patravale VB. Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Delivery Rev, 2007;59:505-21. (Pubitemid 47259228)
13. Delmas F, Di Giorgio C, Elias R, Gasquet M, Azas N, Mshvildadze V, Dekanosidze G, Kemertelidze E, Timon-David P. Antileishmanial activity of three saponins isolated from ivy,α-hederinβ-hederin and hederacolchiside A1, as compared to their action on mammalian cells cultured in vitro. Planta Med, 2000;66:343-7. (Pubitemid 30346298)
14. DNDi. 2008. 2007-2008 Annual report, Drugs for neglected diseases initiative, Geneva, Switzerland.
15. Dutta A, Ghoshal A, Mandal D, Mondal NB, Banerjee S, Sahu NP, Mandal C. Racemoside A. An anti-leishmanial, water-soluble, natural steroidal saponin, induces programmed cell death in Leishmania donovani. J Med Microbiol, 2007;56:1196-204.
16. Frézard F, Demicheli C. New delivery strategies for the old pentavalent antimonial drugs. Expert Opin Drug Deliv, 2010;7(12):1343-58.
17. Galindo-Rodriguez S, Allémann E, Fessi H, Doelker E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res, 2004;21(8):1428-1439. (Pubitemid 39149658)
18. Han K, Lee K-D, Gao Z-G, Park J-S. Preparation and evaluation of poly(Llactic acid) microspheres containing rhEGF for chronic gastric ulcer healing. J Controlled Release, 2001;75:259-69. (Pubitemid 32727257)
19. Herrmann J, Bodmeier R. Biodegradable, somatostatin acetate containing microspheres prepared by various aqueous and non-aqueous solvent evaporation methods. Eur J Pharm Biopharm, 1998;45:75-82. (Pubitemid 28248258)
20. Holzer M, Vogel V, Mäntele W, Schwartz D, Haase W, Langer K. Physicochemical characterisation of PLGA nanoparticles after freeze-drying and storage. Eur J Pharm Biopharm, 2009;72:428-37.
21. Italia JL, Yahya MM, Singh D, Ravi Kumar MNV. Biodegradable nanoparticles improve oral bioavailability of amphotericin B and show reduced nephrotoxicity compared to intravenous Fungizone®. Pharm Res, 2009;26(6):1324-31.
22. Kedzierski L, Sakthianandeswaren A, Curtis JM, Andrews PC, Junk PC, Kedzierska K. Leishmaniasis: Current treatment and prospects for new drugs and vaccines. Curr Med Chem, 2009;16:599-614.
23. Konan YN, Gurny R, Allémann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm, 2002;233: 239-52. (Pubitemid 34230436)
24. Le Pape P. Development of new antileishmanial drugs - current knowledge and future prospects. J Enzyme Inhib Med Chem, 2008;23(5):708-18.
25. Lewis GA, Mathieu D, Phan-Tan-Luu R, 1999. Pharmaceutical experimental design. New York, USA: Marcel Dekker.
26. Maes L, Vanden Berghe D, Germonprez N, Quirijnen L, Cos P, De Kimpe N, Van Puyvelde L. In vitro and in vivo activity of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral Leishmania species. Antimicrob Agents Chemother, 2004;48:130-6. (Pubitemid 38040188)
27. McCarron PA, Donnelly RF, Marouf W. Celecoxib-loaded poly(D,L-lactideco- glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting- out procedure. J Microencapsulation, 2006;23(5):480-98. (Pubitemid 44446591)
28. Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: A review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine, 2010;6(1):9-24.
29. Müller RH, 1990. Colloidal carriers for controlled drug delivery and targeting: Modification, characterization and in vivo distribution. Stuttgart, Germany: Wiss Verl-Ges.
30. Mundargi RC, Babu VR, Rangaswamy V, Patel P, Aminabhavi TM. Nano/ micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Controlled Release, 2008;125:193-209.
31. Murakami H, Kawashima Y, Niwa T, Hino T, Takeuchi H, Kobayashi M. Influence of the degrees of hydrolyzation and polymerization of poly(- vinylalcohol) on the preparation and properties of poly(DL-lactide-coglycolide) nanoparticles. Int J Pharm, 1997;149:43-9. (Pubitemid 27193418)
32. Nagayama S, Ogawara K, Fukuoka Y, Higaki K, Kimura T. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int J Pharm, 2007;342:215-21. (Pubitemid 47259322)
33. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Delivery Rev, 2003;55:329-47. (Pubitemid 36297053)
34. Park TG, Lee HY, Nam YS. A new preparation method for protein loaded poly(D,L-lactic-co-glycolic acid) microspheres and protein release mechanism study. J Controlled Release, 1998;55:181-91. (Pubitemid 28477609)
35. Quintanar-Guerrero D, Allémann E, Fessi H, Doelker E. Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm, 1998;24(12): 1113-28. (Pubitemid 28546092)
36. Rawat A, Burgess DJ. Effect of ethanol as a processing co-solvent on the PLGA microsphere characteristics. Int J Pharm, 2010;394:99-105.
37. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine, 2006;2:8-21.
38. Rocha LG, Almeida JRGS, Macêdo RO, Barbosa-Filho JM. A review of natural products with antileishmanial activity. Phytomedicine, 2005;12: 514-35. (Pubitemid 40755130)
39. Sheng Y, Liu C, Yuan Y, Tao X, Yang F, Shan X, Zhou H, Xu F. Longcirculating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan. Biomaterials, 2009;30:2340-8.
40. Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic "design of experiments". Part I: Fundamental aspects. Crit Rev Ther Drug Carrier Syst, 2004;22(1):27-105.
41. Song KC, Lee HS, Choung IY, Cho KI, Ahn Y, Choi EJ. The effect of type of organic phase solvents on the particle size of poly(D,L-lactide-co-glycolide) nanoparticles. Colloids Surf A, 2006;276:162-7. (Pubitemid 43356167)
42. Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, Cai Z, Li Y, Chen Q. Dual agents loaded PLGA nanoparticles: Systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm, 2008b;69:445-53.
43. Song X, Zhao Y, Wu W, Bi Y, Cai Z, Chen Q, Li Y, Hou S. PLGA nanoparticles simultaneously loaded with vincristine sulphate and verapamil hydrochloride: Systematic study of particle size and drug entrapment efficiency. Int J Pharm, 2008a;350:320-9. (Pubitemid 351146679)
44. Van de Ven H, Vermeersch M, Vandenbroucke RE, Matheeussen A, Apers S, Weyenberg W, De Smedt SC, Cos P, Maes L, Ludwig A. Intracellular drug delivery in Leishmania-infected macrophages: Evaluation of saponin-loaded PLGA nanoparticles. J Drug Target, 2011. doi: 10.3109/1061186X.2011.595491.
45. Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharm Res, 2009;26(5):1025-58.
46. Wong J, Brugger A, Khare A, Chaubal M, Papadopoulos P, Rabinow B, Kipp J, Ning J. Suspensions for intravenous (IV) injection: A review of development, preclinical and clinical aspects. Adv Drug Delivery Rev, 2008;60:939-54.